The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | Challenges in treating patients with HL who relapse after autoSCT & novel therapies being explored
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses the challenges in treating patients with Hodgkin lymphoma (HL) who relapse after autologous stem cell transplantation (autoSCT). Prof. Ansell also highlights treatment approaches being explored for these patients, including novel cellular therapies, novel checkpoint inhibitors, and the role of allogeneic SCT (alloSCT). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
